DERM · Company research
Journey Medical Corporation Common Stock (DERM): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
14records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| An investment adviser reports passive ownership of 2.45M shares in Journey Medical (DERM). - Stock Titan | An investment adviser reports passive ownership of 2.45M shares in Journey Medical (DERM). Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Journey Medical stock reports Q2 revenue of USD 18.51 million - AD HOC NEWS | Journey Medical stock reports Q2 revenue of USD 18.51 million AD HOC NEWS | View source ↗ | AD HOC NEWS | Oct 4, 2026 | neutral | 0 | 0.6 |
| Journey Medical (NASDAQ:DERM) Stock Falls 1.6% - Here's Why - MarketBeat | Journey Medical (NASDAQ:DERM) Stock Falls 1.6% - Here's Why MarketBeat | View source ↗ | MarketBeat | Oct 3, 2026 | neutral | 0 | 0.6 |
| Journey Medical: A Small Pharma With A Large Growth Opportunity (NASDAQ:DERM) - Seeking Alpha | Journey Medical: A Small Pharma With A Large Growth Opportunity (NASDAQ:DERM) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 19, 2026 | neutral | 0 | 0.6 |
| Nine FDA-approved skin drugs are marketed by Journey Medical. Its CEO will join two investor events. - Stock Titan | Nine FDA-approved skin drugs are marketed by Journey Medical. Its CEO will join two investor events. Stock Titan | View source ↗ | Stock Titan | Sep 8, 2026 | neutral | 0 | 0.6 |
| ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy? - Zacks Investment Research | ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy? Zacks Investment Research | View source ↗ | Zacks Investment Research | Aug 25, 2026 | neutral | 0 | 0.6 |
| Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction - Seeking Alpha | Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction Seeking Alpha | View source ↗ | Seeking Alpha | Aug 19, 2026 | neutral | 0 | 0.6 |
| Journey Medical (DERM) Stock Eyes Break Even As Emrosi Gains Traction - Simply Wall Street | Journey Medical (DERM) Stock Eyes Break Even As Emrosi Gains Traction Simply Wall Street | View source ↗ | Simply Wall Street | Aug 14, 2026 | neutral | 0 | 0.6 |
| Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance | Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| DERM Forecast — Price Target — Prediction for 2027 - TradingView | DERM Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes - Yahoo Finance | Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes Yahoo Finance | View source ↗ | Yahoo Finance | Jun 24, 2026 | neutral | 0 | 0.6 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM - PR Newswire | INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM PR Newswire | View source ↗ | PR Newswire | May 7, 2026 | neutral | 0 | 0.6 |
| Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks - Yahoo Finance | Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks Yahoo Finance | View source ↗ | Yahoo Finance | Mar 29, 2026 | neutral | 0 | 0.6 |
| Oddity’s Q3 Beat Signals Rise of Derm-Tech - BeautyMatter | Oddity’s Q3 Beat Signals Rise of Derm-Tech BeautyMatter | View source ↗ | BeautyMatter | Nov 21, 2025 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.